Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study for Assessment of Safety of Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients

NCT00517569 is registered in ClinicalTrials.gov with Genexine, Inc. as lead sponsor.

NCT NCT00517569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00517569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study for Assessment of Safety of Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
Lead sponsor
Genexine, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 2006
Completion date
December 31, 2009
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections